Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Feature
  • Published:

When biotech goes bad

Nature Biotechnology volume 34, pages 284–291 (2016)Cite this article

Subjects

An Erratum to this article was published on 09 June 2016

This article has been updated

A look at 20 years of the dark side of biotech.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Change history

  • 31 March 2016

    In the version of this article initially published, on p.286, in the timeline, far right, “2008 Intercept” should have read “2008 InterMune.” The error has been corrected in the HTML and PDF versions of the article.

Author information

Authors and Affiliations

  1. John Hodgson is Data Editor, Pharma at Informa Business Information, London, UK, and Editor-at-Large, Nature Biotechnology.,

    John Hodgson

Authors
  1. John Hodgson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to John Hodgson.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hodgson, J. When biotech goes bad. Nat Biotechnol 34, 284–291 (2016). https://doi.org/10.1038/nbt.3510

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt.3510

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research